[ET Net News Agency, 17 December 2021] Credit Suisse kept its target price for Innovent
(01801) at HK$90 and maintained its "outperform" rating.
The research house said it expects ADCOM meeting's material release, ADCOM vote, and the
FDA approval decision will serve as three important catalysts for Innovent. (RC)